Skip to main content
padlock icon - secure page this page is secure

Deferasirox for transfusion‐dependent patients with myelodysplastic syndromes: safety, efficacy, and beyond (GIMEMA MDS0306 Trial)

Buy Article:

$59.00 + tax (Refund Policy)

In the absence of randomized, controlled trial data to support iron chelation therapy in transfusion‐dependent patients with myelodysplastic syndromes (MDS), continued evidence from large prospective clinical trials evaluating the efficacy and safety of iron chelation therapy in this patient population is warranted.
No References
No Citations
No Supplementary Data
No Article Media
No Metrics

Keywords: chelation therapy; deferasirox; iron chelation; iron overload; myelodysplastic syndromes; safety; serum ferritin

Document Type: Research Article

Publication date: June 1, 2014

  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
X
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more